INTRODUCTION A major limitation in Alzheimer's disease (AD) research is the lack of the
ability to measure cognitive performance at scale—robustly, remotely, and frequently …

Digital cognitive testing using online platforms has emerged as a potentially transformative
tool in clinical neuroscience. In theory, it could provide a powerful means of screening for …

INTRODUCTION Plasma biomarkers of Alzheimer's disease and related dementias predict
global cognitive performance and decline over time; it remains unclear how they associate …

We investigated whether amyloid-β (Aβ) and tau affected cognition in cognitively normal
(CN) individuals, and whether norms for neuropsychological tests based on biomarker …

There is a pressing need to capture and track subtle cognitive change at the preclinical
stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity …

Background Up to now, there are no clinically available minimally invasive biomarkers to
accurately identify mild cognitive impairment (MCI) patients who are at greater risk to …

Conventional neuropsychological assessments for Alzheimer's disease are burdensome
and inaccurate at detecting mild cognitive impairment and predicting Alzheimer's disease …

Background Plasma biomarkers showed a promising value in the disease diagnosis and
management of Alzheimer's disease (AD). However, profiles of the biomarkers and the …

Digital cognitive assessments, particularly those that can be done at home, present as low
burden biomarkers for participants and patients alike, but their effectiveness in diagnosis of …

INTRODUCTION Remote unsupervised cognitive assessments have the potential to
complement and facilitate cognitive assessment in clinical and research settings. METHODS …